Finding a clinical study that mentions your product's key ingredient feels like progress. In practice, it is the beginning of a process, not the end of one. The study may support a claim, or it may not. The evidence may justify specific wording, or it may require something more qualified. The population studied may or may not match your consumer.
Teams that skip the evaluation process and move directly from "study exists" to "claim approved" consistently create two types of problems: claims that overstate what the evidence shows, and claims that would not survive regulatory scrutiny if challenged. Both are avoidable with a structured five-stage approach.
This guide covers the five stages that turn a clinical study into a claim that is both compelling and defensible.
A clinical study describes what happened under specific conditions to a specific population using a specific protocol. A product claim describes what a consumer can expect from a product they purchase and use in their daily life. These are different statements, and the gap between them is where most clinical claim errors originate.
The role of the claim development process is to close that gap accurately: to identify what the study actually demonstrated, what can honestly be said about the product based on that evidence, and what language accurately conveys the benefit to a consumer without creating expectations the study does not support.
Getting this right matters beyond regulatory compliance. Consumers who encounter a claim that overstates the evidence, and then experience the product, form negative impressions of the brand that affect long-term loyalty. Research on consumer trust in health products consistently shows that credibility, once lost through overclaiming, is expensive to rebuild.
For more on how compliant packaging builds consumer trust over time, see our guide on how compliant packaging protects your brand and ensures customer trust.
The first stage is an assessment of the study itself, before any claim language is drafted. Not every clinical study produces evidence strong enough to support a consumer-facing product claim, and identifying the limitations early prevents the downstream costs of building a claim on inadequate evidence.
Study design determines how much confidence can be placed in the results. The four design variables that matter most for clinical studies and product claims:
Two alignment questions determine whether a study's findings transfer to the marketed product:
Population relevance: Do the study participants match the intended consumer? A study conducted in adults over 60 with a specific health condition cannot directly support a claim targeting healthy adults in their 30s. The claim must reflect the population the study actually tested.
Product and formulation alignment: Does the marketed product deliver the same ingredient, at the same dose, in the same form as what was tested in the study? An ingredient study that tested 500mg of a specific extract cannot support a claim for a product that contains 200mg of a different extract form. This is the most common source of ingredient-level evidence being applied incorrectly to clinical evidence for product claims.
The outcomes measured in the study define the scope of what can be claimed:
A clinical study may contain multiple positive findings. Not all of them become claims. Stage 2 is the process of identifying which results have the properties that support consumer-facing marketing language.
The key principle: claim-worthy findings are those that demonstrate a clear, measurable change directly relevant to the target consumer's experience.
Different types of findings support different types of claims. The four categories, from strongest to most limited:
Map each potential claim to a specific finding from the study before drafting copy. If the mapping cannot be made, the claim is not supportable.
For background on how claim language relates to regulatory expectations, our guide on how to build science-backed product claims covers the broader framework that Stage 2 fits within.
Stage 3 is where the technical language of a clinical study becomes the consumer-facing language of a product claim. The conversion requires precision: every word in the claim must be justifiable by the evidence, and no word should add implications the evidence does not support.
Claim language must match the level of confidence the evidence supports. A practical calibration framework:
The most common error in this stage is addition: adding implications, populations, timeframes, or benefit magnitudes that the study did not test.
Common unsupported additions to avoid:
A claim that accurately reflects the science may still create compliance problems through the way it is presented, the visual context it appears in, or the consumer interpretation it creates. Stage 4 addresses these dimensions before the claim reaches production.
The FTC's substantiation standard assesses claims based on the overall impression they create, not just the literal words used. A technically accurate claim paired with strong visual cues, comparative language, or adjacent copy that implies guaranteed results may create an implied claim that the evidence does not support.
Checklist for full-context claim review:
For a practical framework on how packaging design decisions affect claim interpretation, our article on the biggest packaging compliance challenges and how to solve them covers the intersection of design and regulatory risk in detail.
Every claim that references clinical evidence needs a substantiation file. This file is not just a regulatory formality. It is the record that enables efficient updates when formulations change, when new studies are published, or when regulatory guidance evolves.
A complete clinical evidence file for a product claim includes:
A five-stage process applied once to one product creates one defensible claim. The commercial value of this process is in making it repeatable across product ranges, markets, and regulatory jurisdictions.
Clinical evidence for product claims requires input from more than one function. The team that should be involved in claim approval:
These functions should review the claim simultaneously, not sequentially. Sequential review, where each function sees the claim after the previous one has already approved it, creates pressure to approve what is already partially committed to production.
For teams in pharmaceutical categories, our guide on pharma packaging compliance best practices covers the cross-functional workflow structure that applies specifically to drug and device claim development.
A repeatable process requires documented standards so that each reviewer applies consistent criteria:
Manual cross-functional review scales poorly as product ranges grow. Automated claim review tools address this by running systematic checks on claim language against current regulatory requirements and documented evidence standards at every revision.
GetGenAI's compliance review platform integrates into label development workflows through API, MCP server, or AI assistant skills. For clinical evidence for product claims specifically, this means catching claim language that exceeds what the evidence supports, flagging implied disease claims, and verifying that substantiation documentation requirements are met before files go to production approval.
The five stages above treat the study-to-claim conversion as a technical process, not a creative one. That distinction is important. A defensible clinical study product claim is one where the connection between the evidence and every word of the claim can be traced, documented, and explained to a regulator, a retailer, or a consumer who challenges it.
Brands that build this process before they need to defend a claim spend significantly less time and money than those who build it in response to a challenge. The investment is in the process, not just the claim.
Apply the five stages to your current clinical claims. Identify where the evidence-to-language mapping is clear and documented, and where it relies on assumptions that have never been formally reviewed. Those gaps are where compliance risk accumulates.
Upload your product label to GetGenAI and get an automated compliance review of your claim language against current regulatory standards.
How many clinical studies are usually needed to support a product claim?
The number depends on the claim language. A single well-designed RCT can support "shown in a clinical study to…" language. Claims that use "proven" or "clinically demonstrated" without qualification imply a higher evidence standard, typically multiple consistent studies. The FTC and FDA both assess substantiation based on the entire body of relevant evidence, not just the number of studies, so the quality, consistency, and relevance of studies matter as much as quantity.
What is the difference between a scientific finding and a marketing claim?
A scientific finding describes what was measured and observed under controlled conditions in a defined study population. A marketing claim describes what a consumer can expect from a product in their real-world use. The translation between them requires determining whether the study population matches the target consumer, whether the studied product matches the marketed product, and whether the measured outcome represents a benefit the target consumer would experience. A scientific finding is an input to a claim; it is not the claim itself.
How should companies handle conflicting results between multiple clinical studies?
When studies produce conflicting results, the claim language must reflect the uncertainty rather than selectively citing only the positive studies. The FTC's guidance explicitly states that the weight of evidence should support the claim, which means contradictory evidence must be considered. In practice, this typically means using qualified language that acknowledges the limited or mixed nature of the evidence, avoiding strong efficacy claims when the body of evidence is not consistent, and documenting how conflicting studies were assessed in the substantiation file.
Get intels on brand, platform, and regulatory changes, distilled by our compliance team
